{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:03:04Z","timestamp":1781625784503,"version":"3.54.5"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Treatment of opioid use disorder (OUD) with buprenorphine reduces overdose and all-cause mortality, yet access and retention remain limited. Much of the literature describing barriers to buprenorphine access and retention has focused on practitioner-level or patient-level barriers, but less is known about how potential policy and payment levers may influence prescribing behaviors and treatment practices from the practitioner perspective.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore perspectives among OUD treatment program clinicians and staff about how broader policy and payment structures influence adoption of buprenorphine treatment and low-barrier care practices that promote access and retention.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this qualitative study, semistructured interviews were conducted from December 2022 to July 2023. Participants included clinicians and staff from a range of outpatient treatment programs providing buprenorphine in Philadelphia, Pennsylvania.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Interviews examined prescribing practices and the influence of policy, payment structures, and regulatory requirements on clinical care. Transcripts were analyzed using thematic content analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 28 practitioners and staff (13 men [46%]; 11 [39%] aged 41-50 years), including medical clinicians, therapists, and other administrative staff, were interviewed. Participants included 17 physicians (61%), 7 therapists (25%), 1 advanced practice practitioner (4%), 1 administrator (4%), and 2 other staff (8%). Twenty-four participants (86%) had at least 5 years of experience treating OUD, and all clinicians had obtained a DATA-2000 waiver, also called an X-waiver, to prescribe buprenorphine. Participants viewed the X-waiver as a symbolic barrier, but identified policy factors like insurance coverage, reimbursement rates, payer policies, and licensure requirements as key variables influencing clinical practice. Clinics relied on supplemental funding to sustain care for uninsured patients. Participants reported that payer-imposed requirements, such as prior authorizations and rigid attendance-based reimbursement, undermined timely access and individualized care and that regulatory frameworks often conflicted with harm reduction principles and created staffing and documentation burdens.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This qualitative study of clinicians and staff in buprenorphine treatment programs found that broader policy and payment reforms could help support low-barrier buprenorphine treatment. Enhancing reimbursement, reducing administrative burdens, and aligning licensure and payer policies with evidence-based practices may improve access and retention. These findings offer actionable insights for policymakers, payers, and health systems seeking to address persistent gaps in OUD treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.18878","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:00:24Z","timestamp":1781622024000},"page":"e2618878","source":"Crossref","is-referenced-by-count":0,"title":["Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment"],"prefix":"10.1001","volume":"9","author":[{"given":"Margaret","family":"Lowenstein","sequence":"first","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"University of Pennsylvania Center for Addiction Medicine and Policy, Philadelphia"},{"name":"Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Holliday Davis","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"University of Pennsylvania Center for Addiction Medicine and Policy, Philadelphia"},{"name":"University of Pennsylvania School of Nursing, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Suhail-Sindhu","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"McMurtrie","sequence":"additional","affiliation":[{"name":"Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grande","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hinckley","sequence":"additional","affiliation":[{"name":"Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana V.","family":"Aronowitz","sequence":"additional","affiliation":[{"name":"Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania"},{"name":"University of Pennsylvania School of Nursing, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"zoi260526r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019.","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi260526r3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s11606-020-06448-z","article-title":"Factors associated with long-term retention in buprenorphine-based addiction treatment programs: a systematic review.","volume":"37","author":"Kennedy","year":"2022","journal-title":"J Gen Intern Med"},{"key":"zoi260526r5","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"zoi260526r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi260526r7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States.","volume":"169","author":"Wu","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"zoi260526r8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review.","volume":"35","author":"Mackey","year":"2020","journal-title":"J Gen Intern Med"},{"key":"zoi260526r9","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.70152","article-title":"Primary care\u2019s most pressing needs to address opioid use disorder: A qualitative study.","author":"Robertson","year":"2026","journal-title":"Am J Addict"},{"issue":"3","key":"zoi260526r10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/29767342251320450","article-title":"Insights into recovery: a qualitative analysis of primary care provider perspectives on treating veterans with opioid use disorder in the VA primary care setting.","volume":"46","author":"Scorsone","year":"2025","journal-title":"Subst Use Addctn J"},{"key":"zoi260526r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209623","article-title":"Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing.","volume":"171","author":"Dhanani","year":"2025","journal-title":"J Subst Use Addict Treat"},{"issue":"11","key":"zoi260526r12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.96971","article-title":"Systemic inertia in addiction care: institutional hesitancy and ethical barriers to buprenorphine initiation.","volume":"17","author":"Ram\u00edrez-Rivera","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"zoi260526r13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13722-025-00633-3","article-title":"\u201cThey should be like penicillin\u201d: barriers to the integration of medications for opioid use disorder in specialty treatment programs.","volume":"21","author":"Desai","year":"2025","journal-title":"Addict Sci Clin Pract"},{"key":"zoi260526r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109915","article-title":"\u201cCome try it out. Get your foot in the door:\u201d exploring patient perspectives on low-barrier treatment for opioid use disorder.","volume":"248","author":"Lowenstein","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"zoi260526r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209509","article-title":"Patient and navigator experiences with the opioid use disorder treatment system in Philadelphia, PA.","volume":"167","author":"Reed","year":"2024","journal-title":"J Subst Use Addict Treat"},{"key":"zoi260526r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111130","article-title":"\u201cI want to stay here\u201d: patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care.","volume":"257","author":"Martinez","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi260526r18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment.","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J Addict Med"},{"key":"zoi260526r19","doi-asserted-by":"publisher","DOI":"10.1177\/29768357251371854","article-title":"Low-threshold buprenorphine in non-traditional settings: a scoping review.","author":"Patterson","year":"2025","journal-title":"Subst Use"},{"key":"zoi260526r20","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001672","article-title":"Low-threshold buprenorphine: proposing the ideal service model to engage people with severe opioid use disorder.","author":"Fox","year":"2026","journal-title":"J Addict Med"},{"key":"zoi260526r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103715","article-title":"A mixed methods study of provider factors in buprenorphine treatment retention.","volume":"105","author":"Gertner","year":"2022","journal-title":"Int J Drug Policy"},{"key":"zoi260526r22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2019.06.015","article-title":"Implementation and evaluation of Missouri\u2019s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.","volume":"108","author":"Winograd","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"zoi260526r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements.","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"16","key":"zoi260526r24","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement.","volume":"390","author":"Chua","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260526r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2025.108055","article-title":"Buprenorphine dispensation after X-waiver elimination by clinician specialty.","volume":"69","author":"Stone","year":"2025","journal-title":"Am J Prev Med"},{"issue":"3","key":"zoi260526r26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.mayocpiqo.2024.04.004","article-title":"Trends in the prescribing of buprenorphine for opioid use disorder, 2019-2023.","volume":"8","author":"Savitz","year":"2024","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"21","key":"zoi260526r27","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1001\/jama.2021.4469","article-title":"Concentration of patient care among buprenorphine-prescribing clinicians in the US.","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"key":"zoi260526r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111290","article-title":"Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.","volume":"259","author":"Schuler","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi260526r29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"8","key":"zoi260526r31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1176\/appi.ps.20230522","article-title":"MOUD adoption among clients of organizations that provide MOUD or coordinate care with external providers.","volume":"75","author":"Stewart","year":"2024","journal-title":"Psychiatr Serv"},{"key":"zoi260526r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112586","article-title":"Real-world access to buprenorphine treatment in Philadelphia: a secret shopper study.","volume":"268","author":"Lowenstein","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"zoi260526r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209441","article-title":"Payment-related barriers to medications for opioid use disorder: a critical review of the literature and real-world application.","volume":"165","author":"Bowser","year":"2024","journal-title":"J Subst Use Addict Treat"},{"key":"zoi260526r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209022","article-title":"The role of health plans in addressing the opioid crisis: a qualitative study.","volume":"149","author":"Davis","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"zoi260526r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209213","article-title":"Changes in buprenorphine waivered provider supply after Virginia Medicaid implements the addiction and recovery treatment services program and Medicaid expansion.","volume":"157","author":"Urmi","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"4","key":"zoi260526r38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact.","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J Addict Med"},{"key":"zoi260526r39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2019.07.014","article-title":"Preliminary results of the evaluation of the California Hub and Spoke Program.","volume":"108","author":"Darfler","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi260526r40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/08897077231186212","article-title":"Will the end of the X-waiver expand access to buprenorphine treatment? achieving the full potential of the 2023 Consolidated Appropriations Act.","volume":"44","author":"Saloner","year":"2023","journal-title":"Subst Abus"},{"key":"zoi260526r1","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. The National Academies Press. 2019. Accessed May 7, 2026. https:\/\/www.nationalacademies.org\/projects\/HMD-HSP-18-14\/publication\/25310"},{"key":"zoi260526r4","unstructured":"Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. June 9, 2025. Accessed July 25, 2025. https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html"},{"key":"zoi260526r17","unstructured":"Aronowitz? SV, Behrends? CN, Lowenstein? M, Schackman? B, Weiner? J. Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach. January 2022. Accessed May 7, 2026. https:\/\/ldi.upenn.edu\/wp-content\/uploads\/2022\/01\/Penn-LDI.CHERISH-Issue-Brief.January-2022.pdf"},{"key":"zoi260526r30","unstructured":"The Pew Charitable Trusts. Philadelphia 2024: the state of the city. April 16, 2024. Accessed May 7, 2026. https:\/\/www.pewtrusts.org\/-\/media\/assets\/2024\/04\/philadelphia-2024.pdf"},{"key":"zoi260526r32","unstructured":"City of Philadelphia. Substance use prevention and harm reduction: programs and initiatives. Accessed May 7, 2026. https:\/\/www.phila.gov\/programs\/substance-use-prevention-and-harm-reduction\/"},{"key":"zoi260526r33","unstructured":"Orso? AWA. Mayor Parker proposes cutting nearly $1 million in syringe exchange funding for Prevention Point. Philadelphia Inquirer. April 14, 2024. Accessed May 7, 2026. https:\/\/www.inquirer.com\/politics\/philadelphia\/mayor-cherelle-parker-prevention-point-syringes-funding-20240415.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850416\/lowenstein_2026_oi_260526_1781017032.566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:00:32Z","timestamp":1781622032000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.18878","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}